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A review of planning studies was undertaken to evaluate estimated risks of radiation induced second primary
cancers (RISPC) associated with different prostate radiotherapy techniques for localised prostate cancer. A total of
83 publications were identified which employed a variety of methods to estimate RISPC risk. Of these, the 16
planning studies which specifically addressed absolute or relative second cancer risk using dose–response models
were selected for inclusion within this review. There are uncertainties and limitations related to all the different
methods for estimating RISPC risk. Whether or not dose models include the effects of the primary radiation beam,
as well as out-of-field regions, influences estimated risks. Regarding the impact of IMRT compared to 3D-CRT, at
equivalent energies, several studies suggest an increase in risk related to increased leakage contributing to
out-of-field RISPC risk, although in absolute terms this increase in risk may be very small. IMRT also results in
increased low dose normal tissue irradiation, but the extent to which this has been estimated to contribute to
RISPC risk is variable, and may also be very small. IMRT is often delivered using 6MV photons while conventional
radiotherapy often requires higher energies to achieve adequate tissue penetration, and so comparisons between
IMRT and older techniques should not be restricted to equivalent energies. Proton and brachytherapy planning
studies suggest very low RISPC risks associated with these techniques. Until there is sufficient clinical evidence
regarding RISPC risks associated with modern irradiation techniques, the data produced from planning studies is
relevant when considering which patients to irradiate, and which technique to employ.
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Prostate cancer (PCa) is the most common cancer in
men in Europe and accounts for over one fifth of male
cancer diagnoses [1]. Radiotherapy is one treatment op-
tion for localised and locally advanced PCa and may be
delivered as external beam radiotherapy (EBRT), brachy-
therapy (BT) or combination EBRT and BT (EBRT-BT).
Survival following radical radiotherapy has improved
over the last decade, as a result of dose escalation and
use of androgen deprivation. As survival improves, long
term consequences of treatment become more relevant.
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reproduction in any medium, provided the orradiotherapy is development of a radiation induced sec-
ond primary cancer (RISPC). Newer radiotherapy tech-
niques such as IMRT have facilitated dose escalation,
but differences in dose distribution and scatter have
raised theoretical concerns about an increased risk of
RISPC [2]. The potential risk of RISPC is particularly
relevant in PCa: patients are now diagnosed at an earlier
stage than in the past and so may receive treatment earl-
ier, and patients are surviving for longer. As such, pa-
tients have a longer period in which RISPC may develop.
Some clinical data suggests that irradiated PCa pa-
tients may be at increased risk of RISPC, although the
majority of clinical evidence concerns older EBRT tech-
niques [3-12]. In terms of newer techniques, such as
IMRT, BT and protons, clinical studies examining sec-
ond primary cancers often have relatively low patientLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7,11,13-21]. Until further clinical information is avail-
able, planning studies provide theoretical RISPC risk
estimates.Primary and secondary radiation
Radiation to normal tissues consists of primary radi-
ation, the direct result of the treatment beams, as well as
secondary radiation, which largely affects out-of-field
tissues.
In photon treatments, secondary radiation results from
scatter from within the patient and from the collimator,
as well as leakage from the treatment machine [22-25].
Close to the target, scatter from within the patient is the
main source of secondary radiation, while further from
the target, leakage photons are important [22]. At higher
photon energies (≥10MV), neutrons are produced from
high density materials within the machine head and
these may make a significant contribution to out-of field
secondary dose [26].
For proton treatments, secondary radiation consists of
secondary photons and neutrons produced in the patient
and treatment head, and which indirectly contribute to
out-of-field dose [27]. The relative biological effect, and
thus appropriate radiation weighting factor, that should
be applied to secondary neutrons is a matter of debate
[28]. Secondary neutron production is influenced by
proton delivery technique: spot scanned therapy uses
magnets to direct the beam across a target, while passive
scattering uses a scattering material to ‘spread out’ the
beam. The presence of the scattering material within the
beam causes additional secondary neutron production
which contributes to whole body dose [27,29].Linear no threshold model
Linear plateau model
Linear exponential model
Risk of
radiation 
induced
second 
malignancy
Dose
Figure 1 Illustration of traditional dose-risk models.Modelling second malignancy risk
In low dose out-of-field regions, radiation protection
models are appropriate for estimating RISPC risk. A risk
co-efficient, which reflects the likelihood of developing a
second cancer in a specific organ, is applied to the
equivalent dose received by that organ. The risk co-
efficient is stated in per cent per Sievert and therefore,
as dose increases, the risk of second malignancy in-
creases in a linear fashion. The linear relationship is
based on atomic bomb survivors and on the understand-
ing that cells exposed to lower radiation doses are dam-
aged, but not killed (or sterilised), by radiation, and so
maintain the potential for malignant transformation [2].
Risk co-efficients may be adjusted for age and/or the
population under consideration. A dose and dose-rate
effectiveness factor (DDREF), which adjusts for low
dose and low dose rate situations, (i.e. <100 mGy
or <0.01Gymin-1) may also be applied when estimating
out-of-field RISPC risk in these settings [2,30-35].In higher dose regions the relationship between dose
and risk of second cancer is less certain and a number of
dose–response models are proposed. Models consider
the balance between radiation induced cell damage,
which leaves cells with the potential for malignant trans-
formation, and cell sterilisation which renders cells in-
capable of transformation. The most commonly adopted
models include the linear-no-threshold model (LNT),
the linear-plateau (LP) model and the linear-exponential
(LE) model. All three display a linear dose–response re-
lationship for about the initial 4Gy of fractionated radio-
therapy [2,36]. At higher doses there is variation: the
LNT model presumes an on-going linear relationship at
higher doses [37], the LP model presumes a plateau in
risk beyond the linear portion of the curve, and the LE
model suggests a reduction in the risk at higher doses as
a result of increasing cell sterilisation. In reality, these
models represent extremes, and it is likely that the true
relationship lies somewhere between the LP and LE
models [2]. Neither the LNT, LP nor LE models account
for the effects of fractionation. These three models are
illustrated in Figure 1.
A further model is the competitive risk model which
also encompasses the effects of mutation induction at
lower doses, and cell killing at higher doses. The rela-
tionship is approximately linear at lower doses, but then
begins to fall at higher doses, according to a linear-
quadratic function [38]. This model also accommodates
inhomogeneous dose distributions within an organ and
fractionation.
Organ equivalent dose
The concept of organ equivalent dose (OED) states that
any dose distribution in an organ that results in the
same RISPC incidence as an alternative dose
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employed LE, LP and LNT models. Estimations of
RISPC incorporate age at irradiation, attained age, gen-
der, and fractionation. The model considers radiation
from the primary beam and out-of field components,
which is considered a positive and more realistic move
away from models which only consider out-of-field
doses [39,40]. OED is proportional to RISPC risk. The
OED model is, however, based on a very specific cancer
population (Hodgkin’s disease patients treated with
radiotherapy and chemotherapy), and so the applicability
of this model to other cancer populations has been
questioned [39].
Review
Planning studies were identified from literature review
of Medline (from 1946), EMBASE (from 1947) and
CENTRAL (from 1974) databases. Search terms related
to RISPC, radiotherapy and PCa. The precise search terms
from the Medline search are provided as Additional file 1.
The last search was performed on January 16th 2012.
References and “related articles” were also reviewed. 565
different articles were identified including 83 radiotherapy
planning studies. Within these, various methods were
employed to estimate RISPC risk. This review focuses on
the 16 planning studies (and one more recent study)
which specifically addressed absolute or relative RISPC
risk using dose–response models. The protocol for this
literature review was reviewed by the St James's Institute
of Oncology Radiotherapy Research and Development
Group but no formal ethical committee review was re-
quired as this was a review.
Planning studies
Of the 16 studies, five evaluated out-of-field risk alone,
without consideration of the impact of the primary
beam. This approach has been criticised [37,41] as by
neglecting the impact of the cell sterilisation component
of the primary dose, it may overestimate RISPC. Equally,
however, ignoring the effect of the primary dose could
falsely decrease estimated RISPC risk if risk were actu-
ally to continue to increase beyond 4Gy, rather than
plateau or decrease. Thus the impact of neglecting pri-
mary radiation dose is dependent of the risk model
employed. There is considerable variation amongst the
absolute risks reported from one study to the next.
Differences in risk co-efficients, correction factors, the
region studied (i.e. out-of-field alone or not) and dose–
response models employed undoubtedly contribute. As
the correct dose–response relationship is unknown, it is
impossible to say which study has provided the most
accurate estimates. Nonetheless, data within each study
is valuable when comparing treatments. Many planning
studies have included several dose-risk models in aneffort to demonstrate the range of possible outcomes.
To add to the uncertainty, methods of data collection
have varied amongst studies. For example, when
assessing out-of-field dose, some studies have measured
doses using phantoms, some have used previously pub-
lished measurements, while others have used Monte
Carlo simulations. In terms of assessing dose from the
primary beam, a variety of planning systems and algo-
rithms have been employed. These factors may also con-
tribute to the heterogeneity in RISPC estimates.Impact of IMRT vs. 3D-CRT or conventional RT
Factors of importance when considering the impact of
IMRT on RISPC risk compared to 3D-CRT or conven-
tional radiotherapy include the consequence of a change
in dose distribution and the increase in monitor units
(MU) required to deliver treatment (Figure 2). The dif-
ferent dose distribution has two potential effects. Firstly,
a larger volume of normal tissue is irradiated to lower
doses, which may contribute to increased RISPC risk in
in-field tissues and in tissues in the immediate vicinity
(i.e. tissues within the DVH volume, that is those in-
cluded with the CT planning scan volume; [2,37,42]).
The impact of this on RISPC risk is influenced by the
dose model employed: in theory the LE model predicts
increased RISPC risk as a result of the low dose spread
from IMRT, compared to the relatively high doses and
lack of low dose spread delivered with 3D-CRT (i.e. the
majority of normal tissue dose from 3D-CRT is likely to
fall further along the downward part of the LE curve).
According to the LNT model, which predicts that RISPC
risk will increase with dose, tissues receiving low dose
spread from IMRT which would otherwise not have re-
ceived such a dose with 3D-CRT, will have a higher
RISPC risk. With an LP model, the impact of low dose
spread will depend on whether that dose falls on the
linear part of the curve (where risk increases with in-
creasing dose) or the plateau part (where risk remains
stable). Secondly, however, the improved conformity of
IMRT, and frequently accompanying smaller field sizes,
may result in reduced scatter in nearby out-of-field
tissues (i.e. tissues 15-30 cm from the field edge), thus
reducing RISPC risk [42-44]. IMRT delivery requires
increased MU resulting in increased machine leakage
leading to increased out-of-field dose in tissues further
from the field, which also contributes to RISPC risk. The
relative contribution of the above components deter-
mines the magnitude of RISPC risk. In terms of the high
doses within the PTV, the risk of RISPC (in particular
sarcoma) is thought to remain relatively unchanged
when moving from 3D-CRT to IMRT as there is little
change in the dose distribution within the target region
itself [2].
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Figure 2 Illustration of factors which may impact on the risk of radiation induced second primary cancers when using IMRT instead of
3D-conformal radiotherapy.
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gest that IMRT results in increased RISPC risk (Table 1).
In general, the magnitude of absolute risk has been esti-
mated to be small, but can be more than double that es-
timated for conventional treatments, depending on the
model and whether the primary beam is considered in
addition to out-of-field dose [45,46].
Studies comparing RISPC risk at equivalent energies
have consistently shown an increase in risk with IMRT.
This has largely been attributed to the increase in leak-
age as a result of increased MU requirements [2,45]. In
addition, the increased volume of normal tissue irradi-
ated to a low dose may contribute, although as men-
tioned above, this is a matter of debate [2,37,42]. Insteadof comparing similar energies, the studies by Bednarz et
al and Ruben et al, compared higher energy (18MV)
conformal treatments with lower energy (6MV) IMRT
treatment, and found risks to be comparable [33,42].
Their comparisons are valid, as in practice conformal
plans will often employ higher energies while IMRT is
often delivered using 6MV. It is recognised that at
higher energies there is an increased contribution to
out-of-field radiation from neutron production. The size
of this contribution and thus the absolute impact RISPC
risk, is a matter of debate as a result of uncertainties
regarding the radiation weighting factor which should be
applied to neutrons and differences in the depths at
which neutron doses are measured [45-51]. The
Table 1 Risk of second fatal malignancy with IMRT compared to conventional or 3D-CRT
Study Region assessed§ Method of obtaining dose data Method of risk calculation Energy % Risk of second fatal
malignancy
Conventional/ 3D-CRT IMRT
Followill 1997 [47]¥ Out of field Measured in phantom- previously
published data
Whole body dose equivalent
for neutrons and photons
6MV 0.6%§ 1%
18MV 2.5% 4.5%
NCRP risk coefficients 25MV 4.5% 8.4%
Hall 2003 [2] In field and out of field Scanned volume: calculated from
DVHs (TPS not stated)
LP 6MV 1% 1.75%
LE (with 2 gradients of dose
fall off)Scatter: measured in phantom-
previously published
Kry 2005 [40] Out of field Measured in phantom- previously
published data
Organ specific dose equivalents
for photons and neutrons
6MV NR 2.9%
10MV NR 2.1%
15MV NR 3.4%
NRCP risk co-efficients
18MV 1.7% 5.1%
Based on maximum MU to
generate “conservative
maximum risk estimate”
Schneider 2006
[41]
In field and out of field Scanned volume: calculated from
TPS (Eclipse 7.3.10)
Organ equivalent dose Risk shown is increased risk relative to 15MV 3D-CRT
LE 6MV 15%(LE) 1%(LP)
Photon scatter and neutrons:
measured in phantoms- previously
published data
LP 15MV 20% (LE) 2% (LP)
18MV 60% (LE) 30% (LP)
Kry 2007 [50] Out of field Measured in phantom- previously
published data
Organ specific dose equivalents
for photons and neutrons
(Risk ratio relative to 18MV 3D-CRT and 90% CI in parentheses)
EPA risk co-efficients 6MV with 1.9% (RR:1.4;1.1-1.8)
Based on average MU 10MV 1.5% (RR: 1.1; 0.9-1.3)
15MV 2.2% (RR: 1.6; 1.3-2.0)
18MV 3.6% (RR: 2.7; 2.1-3.2)
Schneider 2007
[49]
In field and out of field Scanned volume: calculated from
TPS (Eclipse 7.3.10)
Organ equivalent dose Increased risk for 100Gy IMRT relative to 70Gy 15MV 3D-CRT
LNT 6MV 18.4% (LE), 15.0% (LP),
22.3% (LNT)LE
15MV 25.3% (LE), 17.0% (LP),
14.1% (LNT)
Photon scatter and neutrons:
measured in phantoms- previously
published data LP
Stathakis 2007 [45] Primary and out of field
photons
Calculated using Monte Carlo
simulations (EGS4/MCSIM) using
whole body CT scans
Whole body dose equivalent 6MV 2.40% (LNT)** 3.55% (LNT)
NCRP risk coefficients 1.13%(LP) 2.65%(LP)
0.93%* 2.46%*Neutron contribution not i
ncluded-likely to increase
risk by 4-10%
LNT
10MV 3.43% (LNT) 4.19%(LNT)LP
1.72%(LP) 3.19% (LP)Out-of-field component only
1.54%* 3.02%*
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Table 1 Risk of second fatal malignancy with IMRT compared to conventional or 3D-CRT (Continued)
18MV 3.54% (LNT) 4.05% (LNT)
1.73%(LP) 3.07% (LP)
1.56%* 2.90% *
Ruben 2008 [42] In field and out of field Scanned volume: calculated from
TPS Plato RTS v1.8 and Plato-ITP
v2.5)
DVH analysis 18MV (3D-CRT) 1% (2.1%) (LP)
Data in parentheses shown for
no correction for PCa patients
with long term survival (i.e. no
reduced weighting)
0.8% (1.5%)(LE)
Rest of body: measured in phantom
Neutrons: measured in phantoms-
previously published data
LP 6MV (IMRT) 0.8% (1.7%) (LP)
LE 0.6% (1.1%) (LE)
Stathakis 2009 [46] In field and out of field Calculated using Monte Carlo
simulations (EGS4/MCSIM) using
whole body CT scan
Whole body effective dose
equivalent.
6MV 2.61%** 3.39%
10MV 2.48% 3.09%
Neutron contribution not
included
NRCP risk co-efficients 18MV 2.24% 2.84%
LNT
Bednarz 2010 [33] Out of field Calculated using Monte Carlo
simulations (MCNPX) using
computational phantom
BEIR VII co-efficients 18MV (3D-CRT: 4 field
box + 6 field boost,
anterior-posterior 4 field
of box delivered using
6MV, rest of fields 18MV)
Risk of second tumour
in:
Stomach: 0.03%
Colon: 0.3%
Oesophagus: 0.07%
Thyroid: 3.1X10-4%
6MV IMRT Risk of second tumour in:
Stomach: 0.04%
Colon: 0.4%
Oesophagus: 0.07%
Thyroid: 1.92X10-4%
Patil 2010 [62] In field Scanned volume: calculated from
TPS (Eclipse 7.3.10)
Organ equivalent dose 6MV No comparator Modal estimate per 10000
person years:
LP
Bladder: 0.1
Rectum: 3.42
Small intestine: 7.789
(Whole body: 129.95***)
¥Patients were treated with pelvic fields for rectal and gynaecological cancers. As prostate cancer patients may also be treated with pelvic RT, this study has been included.
§Figures shown for wedged conventional fields.
*estimations excluding dose to rectum and bladder, i.e. out of field component only.
** conventional four field box.
***: mixed population; includes patients treated for prostate cancer (n = 8) and head and neck cancer (n = 10).
LP: linear plateau LE: linear exponential LNT: linear no threshold; DVH: dose volume histogram.
TPS; treatment planning system; BEIR: Biologic Effects of Ionizing Radiations.
NR: not reported. RR: risk ratio. CI: confidence interval.
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tons may partly explain the lack of difference in risk ob-
served by Bednarz et al and Ruben et al. Comparing
estimated RISPC risk from higher energy (15 or 18MV)
3D-conformal techniques with 6MV IMRT in the other
studies produces mixed results with some studies and
dose–response models (LP) estimating similar levels of
risk [48], some estimating reduced risks [47] and some
estimating a persistently increased risk from 6MV IMRT
[40,45,46,49].
Ruben et al, as above, estimated that risks were similar
between 18MV 3D-CRT and 6MV IMRT based on LP
and LE models [42]. The group found that despite the
increased volume of tissue irradiated to low dose with
IMRT, this did not result in significant increases in
RISPC risk in tissues within the DVH volume. The
group suggested that this could be because the smaller
field sizes and less than 100% beam intensity employed
when delivering IMRT result in reduced scatter within
the patient and from the machine head, which would
compensate for increased leakage as a result of increased
MU requirements. The group also suggested that the
number of MU required to deliver IMRT, was partly
dependent on the software and hardware used. As such,
different hardware/software combinations could result in
increased MU requirements and therefore increased
leakage, which could outweigh any reduction in risk
from reduced scatter secondary to smaller field sizes and
reduced beam intensity [42]. The group went on to fur-
ther investigate out-of-field dose from IMRT compared
to 3D-CRT (albeit using tonsillar radiotherapy plans)
and demonstrated that, as they had suggested, the im-
proved conformity of IMRT resulted in an 11% reduc-
tion in within patient scatter (the effect of which
predominated up to 10 cm from the field edge) but a
five times increase in collimator scatter as a result of in-
creased beam on time (the effect of which predominated
over 10 to 20 cm from the field edge) and a three times
increase in head leakage due to increased MU require-
ments (which predominated beyond 20 cm from the
field edge) [52]. Overall, therefore, IMRT resulted in a
1.8 times increase in out-of-field dose but, importantly,
in absolute terms, this increase in dose was very small
and equivalent to only 0.14% of the prescription dose
[52]. Again, the group suggested that the proportional
and absolute differences in out-of-field dose were de-
pendent on the hardware and software combinations
used, as well as the field sizes employed [52].
Impact of protons vs. photon IMRT or 3D-CRT
Studies estimating RISPC risk following proton treat-
ments have consistently shown a reduction in risk com-
pared with 3D-CRT and IMRT, regardless of whether
spot or passive scanning techniques are used (Table 2).The reduction in risk can be considerable: Yoon et al es-
timated out-of-field RISPC risk from protons to be about
one fifth of that with IMRT, and the risk of rectal or
bladder cancers to be approximately halved [53]. The re-
duction in risk was largely the result of reduced dose to
non-target tissues as a result of the high conformity of
proton treatments which results from reduced exit
doses, which result in a reduction in the volume of nor-
mal tissue irradiated [36]. Close to the field, there was a
reduction in secondary radiation with proton compared
to photon treatments, while at increased distances, the
secondary doses from protons were higher, largely due
to neutron production within the patient and machine
head. The only exception to the above, was demon-
strated by Fontenot et al when a weighting factor of 5
was applied to the neutron absorbed dose [28]. With this
weighting, RISPC risk becomes comparable between
proton and photon treatments. A weighting factor of 5,
however, is not supported by most current evidence
[31,54], and so lower weighting factors, all of which
resulted in reduced risk estimation with protons, can be
considered more realistic. Fontenot et al also calculated
uncertainties associated with risk estimates. In terms of
ratios of excess relative risk (another modelling process
which incorporates the effects of fractionation [55-57]),
there were only small uncertainties related to the dose–
response model employed, while neutron weighting and
inter-patient variability resulted in larger uncertainties
[28]. Overall, uncertainties were in the order of +/−33%.
It should be noted, however, that although RISPC risk
from protons was lower compared to IMRT using both
spot and passive scanning techniques, passive scanning
techniques result in much greater neutron production
and so any reduction in RISPC risk might be less with
spot than passive scanning techniques. Of the studies
reviewed here, none have directly compared RISPC risk
from spot and passive scanning techniques. In addition,
spot scanning has only been compared to 3D-CRT, while
passive scanning has only been compared to IMRT.
Accepting the limitations in the comparison, however,
the reductions in RISPC risk using spot scanning com-
pared to 3D-CRT are in the region of 40 to 50%, while
when comparing passive scanning to IMRT (and when
employing realistic neutron weighting factors), smaller
RISPC risk reductions, in the region of 25 to 40%, are
observed [28,36,48,49].
Impact of tomotherapy
Followill et al estimated out-of-field RISPC risk from
tomotherapy. This study examined pelvic radiotherapy
for rectal and gynaecological primary tumours, but re-
mains relevant for PCa patients receiving pelvic treat-
ments [47]. Risk appeared larger than those estimated
from conventional RT or IMRT at equivalent photon
Table 2 Risk of second fatal malignancy using protons compared to photon treatments
Study Region assessed Method of obtaining dose
data
Method of risk calculation Type of protons
(SS or PS)
Risk of second malignancy from protons
and comparator
Schneider 2006 [48] Primary and out-of-field Proton dose :calculated by TPS
(PSI proton treatment planning
program)
Organ equivalent doses SS Approximately 50% reduction in risk of second
cancer with SS protons compared to 15MV
3D-CRT using both LE and LP modelsLE
Neutron dose: measured in
phantom- previously published
data
LP
Schneider 2007 [49] Primary and out-of field Proton dose :calculated by TPS
(PSI proton treatment planning
program)
Organ equivalent dose SS Risk from 100Gy protons relative to 70Gy
15MV 3D-CRT:
LNT −40.7% (LE)
Neutron dose: measured in
phantom- previously published
data
LE −41.3% (LP)
LP −40.0% (LNT)
Fontenot 2009 [36] Primary and out-of-field Primary dose: calculated by TPS
(Eclipse).
Equivalent doses PS Compared to 6MV step and shoot IMRT, ratio
of excess relative risk with protons:
Ratio of excess relative risk (RRR) 0.61 (small patient)Proton scatter: Monte Carlo
simulations- previously
published BEIR organ specific risk co-efficients 0.66 (medium patient)
0.74 (large patient)Photon scatter:
Measured in phantom- previously
published data
LNT**
Fontenot 2010 [28] Primary and out-of-field Primary dose: calculated by TPS
(Eclipse).
As above PS Compared to 6MV step and shoot IMRT, ratio
of excess relative risk with protons:
Weighting for neutrons also varied
Proton scatter: Monte Carlo
simulations- previously
published
0.66 (95%CI: 0.63-0.69; neutron weighting 1)
0.61 (95%CI: 0.59-0.63; neutron weighting 0.5)
0.75 (95%CI: 0.72-0.78; neutron weighting 2)
Photon scatter: Measured in
phantom- previously published
data
1.03 (95%CI:0.99-1.07; neutron weighting 5)
Total uncertainty in region of +/−33%
Yoon 2010 [53] Out-of-field Measured in phantom Organ equivalent dose PS Relative risk compared to 6MV IMRT:
Stomach: 0.15LP
Lung: 0.17
Thyroid: 0.10
Bladder: 0.40
Rectum: 0.51
SS: spot scanned; PS: passive scanning.
**: LP and LE models also used but results not reported other than similar outcomes with all dose–response models; LNT: linear no threshold; LP: linear plateau; LE: linear exponential; BEIR: Biologic Effects of Ionizing
Radiations; CI: confidence interval.
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creased to 13.1% and 24.4% at 18MV and 25MV respect-
ively. Only out-of-field radiation was considered, and if
the primary beam contribution was also included, risks
might lessen [37].Impact of BT
RISPC risk following BT was estimated by Takam et al
[58]. The group employed the competitive risk model to
estimate risks from differential DVHs for the rectum
and urethra. Estimates were calculated for LDR mono-
therapy (I-125), HDR monotherapy (Ir-192), and com-
bination 3D-CRT with HDR boost (Ir-192). Considering
the rectum and urethra, with LDR-BT, estimated risks
were 2.0x10-4% ± 3x10-4 and 1.3x10-8% ± 7x10-8respect-
ively, and for HDR monotherapy were 1.0x10-4% ±1x10-4
and 2.3x10-8% ±7x10-8. For EBRT-BT, rectal cancer risk
was estimated at 0.06%. Overall, the lowest RISPC risks
were associated with HDR or LDR BT monotherapy,
and were attributed to the high (cell sterilising) equiva-
lent doses received by small regions of neighbouring or-
gans [58]. Unfortunately the group were unable to also
estimate the risk of bladder RISPC as the ultrasound
planning system did not include the whole bladder vol-
ume [58]. In addition, it should be noted that this study
examined RISPC risk for the rectum and urethra only,
and not for all organs or the whole body, as has been
done in other studies, and so direct comparisons with
other studies which have estimated whole body or all
organ risk should be performed with caution.Impact of arc treatments
Alvarez Moret et al examined RISPC risk from quasiI
MAT (intensity modulated arc therapy), a pseudo-rota-
tional techniques employing 36 equally spaced step and
shoot beams to simulate an arc [59]. Estimates were
calculated for quasiIMAT and IMRT using 36 and 72
segments. OED (which is proportional to RISPC risk)
was used, employing LP and LE models, to compare
techniques. OED was similar using both models. For
both IMRT and quasiIMAT, a higher number of seg-
ments resulted in higher OED outside the scanned area
(i.e. out-of-field). Most OED came from the primary
beam (88% with IMRT, 86% with quasiIMAT). OED was
similar with 36 segment quasiIMAT and IMRT. When
72 segments were used there was a small increase in
OED with quasiIMAT but this was not considered
significant. The increase was the result of increased MU
requirements (causing increased leakage) to deliver 72
segment quasiIMAT. Despite the increase in volume of
normal tissue irradiated to a low dose due to the large
number of beams with quasiIMAT, overall, quasiIMAT
did not significantly increase RISPC risk [59].More recently, albeit out with the time-frame of our
search, but included as the only study to examine second
cancer risks associated with actual arc treatements, is
the work by Rechner et al [60]. This group compared
the risks of bladder and rectal RISPC from proton arc
therapy and photon volumetric modulated arc therapy
(VMAT) by calculating ratios of excess relative risks.
DVH data was used to provide details of the therapeutic
dose and out-of-field information was obtained using
previously published data for VMAT, and Monte Carlo
simulations for proton arc therapy. The LNT, LE and LP
models were employed and two different inflexion points
(i.e. the dose beyond which risk is no longer linear with
dose) were examined for the LE and LP models. Proton
arc therapy was found to predict significantly lower risks
of second bladder or rectal cancer according to LE and
LP models with the ratio of excess relative risk (proton
arc therapy:VMAT) as 0.74 and 0.86 using the LE model
with inflexion points after 10Sv and 40Sv respectively,
and 0.84 and 0.91 using the LP model with inflexion
points after 10Sv and 40Sv respectively [60]. There was
no significant difference in second rectal or bladder can-
cer risk when using the LNT model. The group also
compared the calculated excess relative risk of second
bladder and rectal cancer from in-field radiation using
proton arc therapy and VMAT with that previously esti-
mated for IMRT and lateral opposed protons by
Fontenot et al [36]. Numerically, and using a LNT
model, VMAT resulted in lower risks of second bladder
and rectal cancer compared to IMRT (excess relative risk
for bladder RISPC: 5.25 with VMAT and 8.88 with IMRT,
excess relative risk for rectal RISPC: 2.09 with VMAT and
3.32 for IMRT). Proton arc therapy resulted in slightly
higher risks of second bladder or rectal cancer compared
to lateral-opposed proton therapy (excess relative risk for
bladder: 4.86 with proton arc and 3.68 with lateral-
opposed protons, excess relative risk for rectum: 2.74 with
proton arc and 2.01 for lateral-opposed protons) [60].
The impact of the primary and out-of-field doses
As above, studies considering out-of-field doses alone, and
thus neglecting the impact of the primary beam, have been
criticised [37,41]. Omitting the primary beam contribution
(and accompanying cell sterilising doses) potentially results
in over-estimation of RISPC risk if it is the case that at
higher doses the risk of RISPC plateaus or decreases.
Equally, however, if RISPC risk were to continue to in-
crease beyond 4 Gy or so, then omitting the impact of the
primary radiation dose would result in a falsely low RISPC
risk being calculated. Thus the risk model adopted influ-
ences the effect of omitting the primary radiation beam.
Schneider et al, using OED, demonstrated that omitting
the effect of the primary beam resulted in an over-
estimation of risk by a factor of about 2 when considering
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[41]. In contrast, Kry et al, calculated RISPC risk for
6MV and 18MV IMRT plans also using OED, and dem-
onstrated that risk remained similar to that estimated
using out-of-field dose alone [39]. The reasons for these
differences were not fully explained.
Other factors
Other factors which have been examined with regard to
RISPC risk include dose escalation, hypofractionation,
CTV-PTV margin width, collimator angles and photon
energies [40,45-51,58,61]. Detailed discussion is beyond
the scope of this article.
Discussion
All studies acknowledge that there are uncertainties and
limitations in estimating RISPC risk. As such, absolute
values for risk are perhaps less useful than comparisons
between values obtained using the same method. Dose–
response models which encompass the effects of the pri-
mary dose as well as out-of-field doses are considered
more realistic than models only dealing with out-of-field
risks which may over-estimate or under-estimate RISPC
risks depending on the dose–response model employed
and the actual doses received by tissues [37,59]. For
similar energies, several studies suggest that IMRT re-
sults in increased RISPC risk. This has often been attrib-
uted to an increase in MU requirements and head
leakage. Indeed, it has been shown that, compared to
3D-CRT IMRT does result in increased leakage. Further-
more, increased beam on time results in increased colli-
mator scatter, both of which contribute to an increase in
out-of-field dose [52]. IMRT also results in a reduction
in within patient scatter as a result of improved con-
formity and this potentially offsets some of the increase
in risk as a result of increased leakage and collimator
scatter [52]. Overall, however, out-of-field dose from
IMRT does appear to be increased compared to 3D-
CRT, but in absolute terms the increase in dose, and
thus any increase in RISPC form out-of-field dose, is po-
tentially very small [52]. The relative impact of all these
factors depends on the software/hardware combinations
and field sizes employed [42]. The increased volume of
normal tissue receiving low doses with IMRT has also
been thought to contribute to increased RISPC risk in
tissues within the DVH volume but the extent to which
this contributes is influenced by the dose–response
model employed and may, in fact, also be very small
[41,42,59]. While 3D-conformal treatments often use
higher energies to increase penetration (and thus result
in neutron production, contributing to RISPC risk),
IMRT generally uses 6MV, and so the comparison be-
tween 3D-CRT and IMRT should not be restricted to
equivalent energies alone.Despite uncertainties, in general, the absolute risk of
RISPC from IMRT appears small, particularly when esti-
mated with dose models encompassing primary and out-
of-field doses [42,48,62]. Although follow-up and patient
numbers are limited, clinical data supports this sugges-
tion: Huang et al, within a matched pair analysis, dem-
onstrated that patients treated with IMRT or 3D-CRT
compared to surgically treated patients were not at increased
risk of second primary cancers, while patients treated with
2D radiotherapy were at increased risk of second cancers
overall as well as bladder and lymphoproliferative cancers
specifically [13].
Studies involving proton treatments have consistently
shown reduced RISPC risks compared to 3D-CRT and
IMRT, largely because a reduction in exit doses results
in a reduction in the volume of normal tissues irradiated,
thus resulting in improved conformity [28,36,48,49]
Similarly, the risk of RSIPC has been shown to be lower
with proton arc therapy compared to photon VMAT
[60]. Brachytherapy is associated with very low estimated
risks of second rectal cancers [58]. Compared to IMRT,
limited evidence suggests tomotherapy is associated with
higher estimated RISPC risks, while photon arc therapies
(simulated or otherwise) are not [47,59,60].
The ALLEGRO project (full title: Early and late health
risks to normal/healthy tissues from the use of existing
and emerging techniques for radiation therapy) is a col-
laborative project involving 13 European organisations
which aims to clarify some of the uncertainties sur-
rounding modelling and measurement of radiation doses
[63]. The project will ultimately produce clinical recom-
mendations regarding the RISPC risks associated with
current and emerging radiation techniques.
Conclusions
In summary, multiple factors are involved when estimat-
ing RISPC risk, and there are uncertainties in all estima-
tions. At present follow-up from clinical studies is too
short, or patient numbers too small, to determine if the
estimated changes in risk from more modern irradiation
techniques translate into clinically significant changes in
second primary cancer incidence in practice. Until then,
the warnings produced from planning studies must be
borne in mind when considering which patients to ir-
radiate, and which technique to employ.
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